Jeanine (Dienogest, Ethinylestradiol)

• Jeanine, a combined estrogen‑progestogen oral contraceptive, is used in the hormonal regulation of reproduction.
• Contraception: prevents pregnancy by inhibiting ovulation and altering cervical mucus.
• Regulation of menstrual cycles: provides more predictable bleeding patterns.
• Acne management: may improve hormonal acne in women using combined oral contraceptives.

• Dienogest/Ethinylestradiol suppresses the mid‑cycle surge of luteinizing hormone, thereby inhibiting ovulation. It also induces changes in cervical mucus that reduce sperm penetration and alters the endometrial lining to make implantation less likely, providing effective contraceptive action.

Adverse reactions may occur with any hormonal contraceptive. Most are mild and transient.

Common Side Effects

• Nausea: mild stomach upset, often improves with continued use.
• Headache: tension‑type or migraine‑like pain.
• Breast tenderness: swelling or discomfort of the breasts.
• Spotting: irregular bleeding between periods.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins.
• Stroke or myocardial infarction: rare cerebrovascular or cardiac events.
• Severe hypertension: sudden high blood pressure requiring medical attention.

• Before prescribing Jeanine, consider the following safety measures.
• Contraindicated in pregnancy: must not be used by pregnant women.
• Smoking over age 35: avoid use in women who smoke and are older than 35 years.
• Cardiovascular risk: assess history of thromboembolic disease before initiation.
• Liver disease: use with caution in patients with hepatic impairment.
• Drug interactions: review concomitant medications that may affect efficacy.
• Store at ambient temperature: keep below 25°C, protect from moisture and light.

Jeanine can interact with several medicines, altering its effectiveness or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce contraceptive efficacy.
• Other estrogen‑containing products (e.g., hormone therapy): increase risk of estrogen‑related adverse events.
• Anticoagulants (e.g., warfarin): may enhance anticoagulant effect and bleeding risk.

Moderate Interactions (Monitor Closely)

• Antifungals such as ketoconazole: may increase hormone levels.
• Macrolide antibiotics (e.g., erythromycin): possible modest reduction in contraceptive effect.
• Selective serotonin reuptake inhibitors (e.g., fluoxetine): may affect hormone metabolism.